Franz-Werner Haas, CureVac CEO (Christoph Schmidt/picture-alliance/dpa/AP Images)

Cure­Vac blames vari­ants as a close­ly-watched Covid vac­cine goes down in flames, fail­ing piv­otal study with woe­ful da­ta

Cure­Vac was wide­ly ex­pect­ed to come in with a late but like­ly late-stage win­ner in the race to de­vel­op new vac­cines for the Covid-19 pan­dem­ic. In­stead, late Wednes­day, the Ger­man biotech said their mR­NA can­di­date CVn­CoV flat failed a piv­otal tri­al — quash­ing any hopes for a quick en­try in the block­buster field and gut­ting their share price.

CVn­CoV demon­strat­ed an in­ter­im vac­cine ef­fi­ca­cy of 47% against COVID-19 dis­ease of any sever­i­ty and did not meet pre­spec­i­fied sta­tis­ti­cal suc­cess cri­te­ria. Ini­tial analy­ses sug­gest age and strain de­pen­dent ef­fi­ca­cy.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.